A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models

Aïda Falgàs,1,2,* Victor Pallarès,1,3,* Ugutz Unzueta,1,2 María Virtudes Céspedes,1,2 Irene Arroyo-Solera,1,2 María José Moreno,2 Alberto Gallardo,1,4 Maria Antonia Mangues,2 Jorge Sierra,3,6 Antonio Villaverde,2,7,8 Esther Vázquez,2,7,8 Ramon Mangues1,2,6,* and Isolda Casanova1,2,6

1Biomedical Research Institute Sant Pau (IIB-Sant Pau), Hospital de la Santa Creu i Sant Pau; 2CIBER en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN); 3Department of Hematology, Hospital de la Santa Creu i Sant Pau; 4Department of Pathology, Hospital de la Santa Creu i Sant Pau; 5Department of Pharmacy, Hospital de la Santa Creu i Sant Pau; 6Josep Carreras Research Institute; 7Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona and 8Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona, Barcelona, Spain

*AF and VP contributed equally to this work.

ABSTRACT

One-third of diffuse large B-cell lymphoma patients are refractory to initial treatment or relapse after rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy. In these patients, CXCR4 overexpression (CXCR4+) associates with lower overall and disease-free survival. Nanomedicine pursues active targeting to selectively deliver antitumor agents to cancer cells; a novel approach that promises to revolutionize therapy by dramatically increasing drug concentration in target tumor cells. In this study, we intravenously administered a ligand-ed protein nanocarrier (T22-GFP-H6) targeting CXCR4+ lymphoma cells in mouse models to assess its selectivity as a nanocarrier by measuring its tissue biodistribution in cancer and normal cells. No previous protein-based nanocarrier has been described as specifically targeting lymphoma cells. T22-GFP-H6 achieved a highly selective tumor uptake in a CXCR4+ lymphoma subcutaneous model, as detected by fluorescent emission. We demonstrated that tumor uptake was CXCR4-dependent because pretreatment with AMD3100, a CXCR4 antagonist, significantly reduced tumor uptake. Moreover, in contrast to CXCR4– subcutaneous models, CXCR4+ tumors did not accumulate the nanocarrier. Most importantly, after intravenous injection in a disseminated model, the nanocarrier accumulated and internalized in all clinically relevant organs affected by lymphoma cells with negligible distribution to unaffected tissues. Finally, we obtained antitumor effect without toxicity in a CXCR4+ lymphoma model by administration of T22-DITOX-H6, a nanoparticle incorporating a toxin with the same structure as the nanocarrier. Hence, the use of the T22-GFP-H6 nanocarrier could be a good strategy to load and deliver drugs or toxins to treat specifically CXCR4-mediated refractory or relapsed diffuse large B-cell lymphoma without systemic toxicity.

Introduction

Diffuse large B-cell lymphoma (DLBCL) represents 30-33% of all non-Hodgkin lymphomas (NHL).1 Management of DLBCL has been improved by the addition of rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy. However, despite this advancement, R-CHOP treatment is still associated with high toxicity, relapse and an unacceptably high treatment failure
rate. Relapse after R-CHOP therapy occurs in 40% of patients, this is currently managed with salvage chemotherapy. This is followed by high-dose chemotherapy and autologous bone marrow transplant in patients with chemosensitive disease, which, however, leads to long-term disease control in only half of the patients. Moreover, less than 20% of patients treated with an R-CHOP front-line regimen who relapse within one year benefit from salvage autologous hematopoietic cell transplant. Thus, novel therapeutic strategies that reduce relapse rates and enhance DLBCL patient survival are urgently needed.

Novel approaches based on selective-drug delivery to cancer cells promise to increase patient benefit by offering both higher cure rates and lower side effects in DLBCL patients. In this regard, we evaluated a previously developed protein nanocarrier as a possible drug carrier to pursue the selective elimination of DLBCL cells over-expressing CXCR4 (CXCR4+), which are responsible for DLBCL relapse and disease progression. Thus, the CXCR4-CXCL12 axis is involved in tumor pathogenesis, cancer cell survival, stem cell phenotype, and resistance to chemotherapy. In addition, CXCR4 is constitutively over-expressed in NHL cell lines, and also in approximately 50% of malignant B-cell lymphocytes derived from DLBCL patients. Interestingly, CXCR4+ DLBCL cell lines show resistance to rituximab but are sensitive to the combination of rituximab with a CXCR4 antagonist. Most importantly, we and others reported that CXCR4 overexpression associates with poor progression-free and overall survival in DLBCL patients treated with R-CHOP.

Our group has developed T22-GFP-H6, a self-assembling protein nanocarrier, which uses the peptidic T22 ligand to target the CXCR4 receptor. This carrier displays a high recirculation time in blood and selectively biodistributes to tumor tissues in solid tumor models, internalizing selectively in CXCR4+ cancer cells, while increasing its tumor uptake compared to the untargeted GFP-H6 counterpart. This nanocarrier is also able to incorporate toxins (e.g., diphtheria toxin catalytic domain) leading to selective elimination of CXCR4+ colorectal cancer cells. Nevertheless, no previous protein-based nanocarrier has been described to specifically target cancer cells in hematologic neoplasias. Critical differences between solid cancers and hematologic neoplasias may raise doubts about its use to target CXCR4+ cancer cells in DLBCL models. Thus, the enhanced permeability/reten-

**Methods**

**In vivo experiments**

Four-week old female NOD/SCID mice were obtained from Charles River Laboratories. Mice were maintained in specific pathogen-free (SPF) conditions with sterile food and water ad libitum. Mouse experiments were approved by the Hospital de la Santa Creu i Sant Pau Animal Ethics Committee. For SC models, 10 million DLBCL cells were injected in both flanks. Tumor growth was monitored twice a week with a caliper (tumor volume = width² x length/2). When tumors reached a volume of 600-800 mm³, mice received a single intravenous (IV) dose of 200 µg T22-GFP-H6, which contains a fluorescent domain, or buffer (20 mM Tris, 500mM NaCl, pH 8). T22-GFP-H6 design and production have been described in previous studies. Fluorescence intensity (FI) was measured ex vivo at different time points in tumors, plasma, and all organs. A plasma pool was obtained by centrifugation of total blood, obtained by intracardiac puncture (25G), at 600g for ten minutes (min) at 4°C. T22-GFP-H6 biodistribution in SC tumors over time was measured using the area under the curve (AUC). AUC analysis of tumors and normal organs was measured using the GraphPad Prism 6 program. We subcutaneously administered AMD3100 in mice to perform CXCR4 blocking experiments, giving a total of three AMD3100 doses at 10 mg/kg, 1 hour before and 1h and 2h after IV T22-GFP-H6 injection. We used SC tumor models to evaluate the antitumor effect and associated toxicity of T22-DITOX-H6. Mice received a single 25 µg IV dose of T22-DITOX-H6 or buffer when tumors reached a volume of 400-600 mm³. Animals were euthanized 24h post administration. T22-DITOX-H6 nanoparticle characterization has been published previously.

To generate the disseminated lymphoma model, NOD/SCID mice were intravenously injected with 20x10⁶ luminescent Toledo cells (Toledo-Luci) in 200 µL physiological serum. Dissemination was monitored capturing bioluminescence intensity (BLI) twice a week after intraperitoneal injection of firefly D-luciferin. After 27-30 days, animals received a single IV dose of 400 µg T22-GFP-H6 nanocarrier or buffer. Five hours later, FLI was measured ex vivo in all organs. Fluorescence intensity correlates to the amount of accumulated protein in each tissue and is expressed as average radiant efficiency. FLI from experimental mice was calculated subtracting the FLI auto-fluorescence of control mice. The emitted FLI and BLI were measured using the IVIS Spectrum 200 Imaging System (Xenogen). Finally, tumors and all organs were collected, fixed and paraffined to perform histological, immunohistochemical or immunofluorescent evaluations, and were also directly cryopreserved in liquid nitrogen for protein extraction.

Details of methods for cell culture, transfection with Luciferase and CXCR4 plasmids, cell proliferation, flow cytometry, western blot, histopathology, 4′,6-diamidino-2-phenylindole (DAPI) staining, immunohistochemistry (IHC) and immunofluorescence (IF) analyses can be found in the Online Supplementary Appendix.
Statistical analysis

*In vitro* experiments were performed in biological triplicates while *in vivo* experiments were performed in triplicates/quadruplicates. The data for all experiments were reported as mean ± Standard Error of Mean (SEM). All results were analyzed using the Student t-test. *P*<0.05 was considered statistically significant. Statistical calculations were performed using SPSS software version.21

Results

**CXCR4-dependent internalization of T22-GFP-H6 in human CXCR4+ diffuse large B-cell lymphoma cell lines**

CXCR4 membrane levels were evaluated in four human DLBCL cell lines by flow cytometry (Figure 1A) and IHC (Online Supplementary Figure S1). CXCR4 expression was highest in Toledo cells, followed by U-2932 and RIVA, whereas CXCR4 expression in the SUDHL-2 cell line was undetectable. CXCR4-transfected SUDHL-2 cells (CXCR4+ SUDHL-2) showed average CXCR4 levels.

T22-GFP-H6 nanocarrier internalization correlated with CXCR4 expression. Thus, T22-GFP-H6 internalized the most in Toledo cells, followed by U-2932 and RIVA, whereas it did not internalize in SUDHL-2 (Figure 1B). Moreover, T22-GFP-H6 nanocarrier internalization was CXCR4-dependent. So, after preincubation with CXCR4 antagonist AMD3100, T22-GFP-H6 internalization decreased significantly in Toledo, U-2932 and RIVA cells (Figure 1C). As expected, T22-GFP-H6 did not internalize in SUDHL-2 cells (only background FLI was detected), whereas high internalization was registered in CXCR4+ SUDHL-2 cells. Similarly, AMD3100 preincubation had no effect on nanocarrier internalization in SUDHL-2 cells but led to a significant decrease in CXCR4+ SUDHL-2 cells (Figure 1D). Thus, we showed specific *in vitro* entry of T22-GFP-H6 into CXCR4+ DLBCL cells through the CXCR4 receptor.

**Non-cytotoxic effect of T22-GFP-H6 in diffuse large B-cell lymphoma cell lines in vitro**

After exposure to T22-GFP-H6 (50-500 nM range), cell viability for all four evaluated DLBCL cell lines was approximately or above 100% (Figure 1E). Therefore, T22-GFP-H6 nanocarrier has no *in vitro* antineoplastic effect against these DLBCL cell lines.

Figure 1. *In vitro* T22-GFP-H6 nanocarrier internalization in CXCR4+ diffuse large B-cell lymphoma (DLBCL) cell lines and its dependence on the CXCR4 receptor. (A) CXCR4 membrane expression of different DLBCL cell lines (Toledo, U-2932, RIVA and SUDHL-2) and the SUDHL-2 cell line transfected with a CXCR4 plasmid (CXCR4+ SUDHL-2) measured by flow cytometry. (B) Levels of intracellular fluorescence quantified by flow cytometry in Toledo, U-2932 and RIVA cells after 1 hour (h) exposure to T22-GFP-H6 nanocarrier at different concentrations (range: 0.1 nM-250 nM). (C) T22-GFP-H6 internalization, measured by flow cytometry, in Toledo, U-2932 and RIVA cells after 1 h pretreatment with the antagonist AMD3100 (50 nM T22-GFP-H6:500 nM AMD3100). (D) Competition assays with AMD3100 (250 nM T22-GFP-H6: 2500 nM AMD3100) in SUDHL-2 cells and CXCR4+ SUDHL-2 cells. (E) Lack of cytotoxicity (measured as percentage of cell viability) after 48h exposure to high concentrations of T22-GFP-H6 nanocarrier (range: 50 nM-500 nM) in Toledo, U-2932, RIVA and SUDHL-2 cells. *P*<0.05; **P**<0.01; ***P***<0.001; ns: non-significant; MFI: mean fluorescence intensity.
Figure 2. In vivo biodistribution and toxicity assessment of T22-GFP-H6 in the CXCR4+ subcutaneous (SC) Toledo mouse model. (A) Fluorescence intensity (FLI) detection in SC Toledo tumors at 2, 5 or 24 hours (h) after intravenous (IV) injection of 200 mg of T22-GFP-H6. No fluorescence was detected in buffer-treated mice. (B) Quantification of emitted fluorescence (measured as FLI ratio) at different times (2, 5 and 24h) in SC tumors and normal tissues (liver, spleen, heart, lungs, kidneys and bone marrow). (C) FLI emitted by the nanocarrier in normal tissues 5h after T22-GFP-H6 administration. (D) Hematoxylin & Eosin (H&E) stained tissue sections of normal organs and SC tumors at the 5h FLI peak. (E) Representation of the area under the curve (AUC) of emitted FLI over time (2-24h) registered in tumors, liver and lungs in T22-GFP-H6-treated mice. Notice that the AUC in the organs with an uptake lower than 2% (spleen, kidney, heart and BM) is not visible in this graphic. (F) Percentage of nanocarrier uptake (as measured by the AUC of emitted FLI) registered in each organ studied in relation to the total emitted FLI (sum of AUC in tumors and all studied normal organs) during the 2-24h period and expressed as mean±Standard Error of Mean (SEM). FLI ratio for experimental mice was calculated subtracting the FLI auto-fluorescence of control mice and dividing the FLI signal of each tumor/tissue by the FLI signal of the lungs (organ chosen as reference). Original magnification x400. BM: bone marrow.
Highly selective T22-GFP-H6 tumor uptake in mice bearing subcutaneous CXCR4+ diffuse large B-cell lymphoma tumors without toxicity

We evaluated T22-GFP-H6 biodistribution in the CXCR4+ SC Toledo mouse model, measuring the fluorescence emitted by the nanocarrier GFP domain, after a single 200 µg IV dose. T22-GFP-H6 accumulated in CXCR4+ SC tumors 2h after injection, reaching a FLI peak 5h post injection, and decreasing considerably after 24h (Figure 2A and B). Tumor uptake 5h post injection was 35.85 times higher than lung uptake, which was taken as a reference among the normal mouse organs because, although almost negligible, it did show the most sustained FLI emission over time (Figure 2B and Online Supplementary Table S1). Similar observations were made in all non-tumor organs analyzed (Figure 2B and C). Moreover, we did not observe any histological alteration in Hematoxylin & Eosin (H&E) stained normal organs (Figure 2D).

The quantification of the AUC of emitted FLI over the study period (Figure 2E and Online Supplementary Table S2) showed that tumor tissue accumulated 86.13±4.04% of the total FLI detected in all organs, including tumor and non-tumor tissues. In contrast, the liver, which was the non-tumor organ with higher AUC, reached only 5.96±2.83% (Figure 2F). Therefore, T22-GFP-H6 displayed a specific targeting of CXCR4+ SC DLBCL tumors with negligible nanocarrier accumulation in non-tumor bearing organs, which supports a highly selective tumor uptake as compared to normal cells.

After a single T22-GFP-H6 IV administration, measurement of circulating nanocarrier showed a fast biodistribution half-life (t1/2≈20min) in the blood compartment, followed by a slower elimination phase (t1/2≈75min), becoming undetectable in plasma at 2h (Figure 2A and B).

The highly unusual T22-GFP-H6 tumor uptake and its low accumulation in the expected non-tumor drug clearance organs (i.e. liver and kidney) triggered the analysis of the nanocarrier fate in these organs by western blot. After a single T22-GFP-H6 dose, we observed the full-length protein (~30kDa) present in liver and kidney 10min post administration (Figure 3C and D), becoming undetectable over a period which ranged from 30min to 48h. In sharp contrast, we detected full-length T22-GFP-H6 protein in Toledo SC tumors at 10min, 30min, 2h and 5h. Interestingly, faint proteolytic bands appeared over a period which ranged from 30min to 2h, which became more intense at 5h. Over a period which ranged from 15h to 48h, the full-length protein decreased dramatically and the nanocarrier was mostly proteolyzed (Figure 3E). These results, together with the observed FLI AUC in tumor and normal organs, suggest that the proteolytic activity observed in the tumor makes it the main nanocarrier clearance organ.

T22-GFP-H6 and CXCR4 receptor co-localization in the cell membrane followed by its internalization in CXCR4+ diffuse large B-cell lymphoma cells

At the FLI peak (5h) after a single 200µg injection, we observed nanocarrier internalization in 56.2±12.0% of the Toledo cells (green staining with anti-GFP IF) in tumors, whereas all (100%) tumor cells over-expressed CXCR4 (red staining with anti-CXCR4 IF). In buffer-treated tumors, the CXCR4 receptor localized mainly at Toledo cell membrane, while a dot-like staining inside the cell cytosol was observed in the nanocarrier-treated-tumors; a finding consistent with receptor internalization within endocytic vesicles. Merged (yellow) images showed nanocarrier and CXCR4 co-localization in the membrane of Toledo cells in T22-GFP-H6-treated tumors. Once into the cytosol, the CXCR4 and T22-GFP-H6 stained endo-
vesicles were dissociated (Figure 4). These results suggest that T22-GFP-H6 interacts with the CXCR4 receptor in the cell membrane, where both co-localize and, after internalizing jointly within endosomal vesicles, they are able to release the nanocarrier in the CXCR4+ DLBCL cell cytosol.

Selective CXCR4-dependent T22-GFP-H6 tumor uptake in subcutaneous diffuse large B-cell lymphoma tumors

We also assessed the dependence of nanocarrier tumor uptake on CXCR4 receptor, performing in vivo competition assays using the CXCR4 antagonist AMD3100 in mice bearing CXCR4+ Toledo-derived SC tumors (Figure 5A). Five hours after T22-GFP-H6 administration, we registered a peak of nanocarrier accumulation in tumors that reached 3.23±0.38E7. In contrast, the AMD3100 administration prior and after nanocarrier injection blocked nanocarrier uptake in tumors, since the emitted FLI was 10 times lower (0.31±0.52E7) (Figure 5B). Differences between the Toledo tumors treated with T22-GFP-H6 and those treated with AMD3100 plus T22-GFP-H6 were highly significant (Figure 5C). This inhibition of nanocarrier uptake by AMD3100 confirms that tumor uptake depends on the CXCR4-receptor.

Additional support for this selective uptake comes from additional biodistribution assays comparing CXCR4– SUDHL-2 and CXCR4+ SUDHL-2 SC tumor-bearing mice. Five hours after 200 mg T22-GFP-H6 administration, FLI emission from CXCR4+ SUDHL-2 tumors was significantly higher (2.12±0.46E7) than from CXCR4– SUDHL-2 tumors (0.04±0.21E7) (Figure 5C and D). Consistently, Toledo and CXCR4+ SUDHL-2 tumors showed CXCR4 membrane expression, as measured by IHC, whereas CXCR4– SUDHL-2 tumors did not (Figure 5E); a finding that confirms the specific directioning of T22-GFP-H6 to tumors containing CXCR4+ DLBCL cells.

T22-GFP-H6 biodistributes to all diffuse large B-cell lymphoma-infiltrated organs and internalizes in lymphoma cells in a CXCR4+ diffuse large B-cell lymphoma disseminated mouse model

We evaluated the biodistribution of T22-GFP-H6 in vivo in a CXCR4+ Toledo-Luci disseminated DLBCL mouse model, while monitoring lymphoma cell dissemination by measuring BLI levels emitted by the infiltrated organs in vivo (Figure 6A). In addition, we precisely identified the organs showing infiltration by Toledo-Luci cells, BM (cranium and hind limbs) and LN (cervical and renal). In some mice (57.5%), we detected residual BLI levels in the spleen and no infiltration was observed in any other organ (Figure 6B). Macroscopic LN (cervical and renal) infiltration was identified in 100% of mice (Figure 6C). H&E staining and anti-CD20 IHC confirmed Toledo-Luci cell infiltration in BM and LN tissue sections. CXCR4 membrane expression was maintained in DLBCL cells located in all infiltrated organs (Figure 6D).

We went on to study T22-GFP-H6 biodistribution after IV injection (400 µg dose) or buffer in mice displaying complete dissemination of Toledo cells (27-30 days post injection). Five hours after nanocarrier injection, we observed high FLI in BM (cranium and hind limbs) and LN (renal and cervical), whereas fluorescence was negligible or undetectable in non-infiltrated organs (Figure 7A and B). Indeed, T22-GFP-H6 was specifically delivered to the DLBCL infiltrated organs since FLI levels in BM and LN were 31.05- and 12.98-fold higher, respectively, in comparison to lungs (the reference organ showing background FLI levels) (Figure 7B and Online Supplementary Table S3). Moreover, no histopathological alterations were observed in any tissue analyzed in nanocarrier-treated mice (data not shown). IP analysis using anti-GFP showed T22-GFP-H6 (green) in Toledo-Luci cell cytosol in affected BM and LN. In addition, CXCR4 dot-like (red) and nanocarrier (green)
staining co-localized (yellow) on the cell membrane. Moreover, similar to findings in SC Toledo tumors, in the disseminated model, we found a release of the nanocarrier into CXCR4+ DLBCL cell cytosol separated from endocytic vesicles containing the CXCR4 receptor (Figure 7C).

T22-GFP-H6 internalization in CXCR4+ mouse cells
To support the relevance of our CXCR4+ DLBCL models for clinical translation of the tumor (human cells) and non-tumor (mouse cells) biodistribution data, we assessed whether the nanocarrier internalized in mouse cells.
Firstly, we evaluated CXCR4 expression in the mouse B-cell lymphoma WEHI-231 cell line that showed medium CXCR4 membrane expression by flow cytometry and IHC (Online Supplementary Figure S2A). Then, we demonstrated intracellular nanocarrier uptake in mouse WEHI-231 cells and its dependence on CXCR4 expression, since it was inhibited by AMD3100 (Online Supplementary Figure S2B). Therefore, T22-GFP-H6 internalizes in both CXCR4+ human and CXCR4+ mouse lymphoma cells.

**T22-DITOX-H6 antitumor effect and lack of toxicity in a CXCR4+ subcutaneous diffuse large B-cell lymphoma mouse model**

Finally, we evaluated whether the therapeutic nanoparticle T22-DITOX-H6, incorporating a toxin domain with known antitumor activity, induced cell death of Toledo cells in SC tumors without damaging normal cells. T22-DITOX-H6 caused apoptosis in lymphoma cells in these tumors since a single IV 25 μg T22-DITOX-H6 dose signif-

![Figure 6. Pattern of organ infiltration in the Toledo-Luci diffuse large B-cell lymphoma (DLBCL) disseminated mouse model.](image)
Significantly increased the number of apoptotic bodies and cleaved PARP level compared to buffer-treated mice (Figure 8A and B).

We then confirmed CXCR4 expression in hematopoietic cells of the mouse BM (CXCR4+ CD20- staining) (Figure 8C). A direct comparison showed that CXCR4 expression in SC Toledo tumors was significantly (22.87 times) higher than CXCR4 in mouse BM hematopoietic cells (Online Supplementary Figure S2C and D). No histopathological alterations (H&E) nor induction of cell death (DAPI stain-
ing) was observed in the BM of T22-DITOX-H6-treated mice (Figure 8C). Lastly, we did not find any macroscopic (data not shown) or microscopic (H&E staining) alteration in liver and kidneys (Figure 8D). Our results support the use of the nanocarrier under examination to efficiently deliver antitumor agents to achieve the selective killing of CXCR4+ lymphoma cells without inducing toxicity on CXCR4+ mouse hematopoietic cells or systemic organs.

Figure 8. Evaluation of T22-DITOX-H6 antitumor effect and toxicity in a CXCR4+ subcutaneous (SC) Toledo mouse model. (A) Apoptosis detection by cleaved Poly(ADP-ribose) polymerase (PARP) immunohistochemistry (IHC) as well as nuclear condensation by 4′,6-diamidino-2-phenylindole (DAPI) staining. (B) Mean quantification of cleaved PARP stained area (above) and number of apoptotic bodies by DAPI staining (bottom) in SC Toledo tumors 24 hours (h) after treatment with buffer or a single intravenous (IV) injection of 25 µg T22-DITOX-H6. (C) Lack of T22-DITOX-H6-induced toxicity in mouse bone marrow (BM). Human anti-CD20 and mouse anti-CXCR4 IHC assays were used to identify CXCR4+ mouse cells resident in BM. Hematoxylin & Eosin (H&E) and DAPI staining samples were examined to detect possible alterations in cell morphology or cell death induction. (D) Lack of systemic toxicity in liver or kidney by histological analysis of tissue sections H&E 24h after treatment with buffer or 25 µg T22-DITOX-H6. All images were taken at x400 and inserts at x1000. *P<0.05.
Discussion

A huge limitation for the clinical translation of nanomedicines in oncology is the fact that only 0.7-5.0% of the administered dose reaches the tumor. In contrast, our biodistribution studies show a very high level of T22-GFP-H6 uptake in tumor tissue (86.1% of the total emitted fluorescence) compared to the combined fluorescence emitted by all normal tissues (15.9% of total tumor+non-tumor fluorescence), including the spleen, liver, kidney, heart, lung and BM. We have recently reported a similar finding for the same nanocarrier in a SC colorectal cancer (CRC) model. These data are consistent with the fast biodistribution half-life for the nanocarrier in blood (approx. 20 min) and the detection of the full length protein in the 10min-5h period in SC CXCR4+ DLBCL tumors. Unexpectedly, we found that most of the proteolytic metabolism of T22-GFP-H6 occurs in tumor tissues, whereas clearance in liver or kidney is negligible, being detectable in these organs at 10 min, probably by accessing the fenestrated vessels during a short time period, but being unable to reach their parenchyma. Our data are in dramatic contrast to the reported biodistribution of most nanocarriers studied so far, regardless of whether this was targeted actively or passively.

Nowadays, most nanocarriers that transport medicinal drugs in clinical trials, or that are available on the market, use passive targeting (e.g. liposomal doxorubicin or albumin-paclitaxel). They enhance the drug antitumor effect because its particulate size increases its permeability and retention in the tumor (EPR effect). Nevertheless, 50-80% of these nanocarriers accumulate in the liver. Although still at an initial stage, active nanocarrier targeting is being developed to selectively deliver antitumor drugs to tumor cells through specific surface receptors. Regarding B-cell lymphoma therapy, the use of doxorubicin-loaded mesoporous silica nanoparticles bound to rituximab, for targeting CD20+ B cells, demonstrated a significant increase in doxorubicin tumor uptake and higher inhibition of tumor growth than free doxorubicin. Moreover, additional targeted and non-targeted therapeutic nanoparticles are currently being evaluated for treatment of B-cell malignancies; however, no efficacy data are available yet because Phase I clinical assays to test their tolerability are still ongoing.

The strategy we have used here with the actively targeted T22-GFP-H6 nanocarrier achieves selective and enhanced biodistribution to tumor tissue with no toxicity in the non-tumor organs. One possible explanation for the enhanced T22-GFP-H6 tumor uptake relates to the nature of the nanocarrier material. While our nanocarrier is made of self-assembled proteins, most, if not all, nanocarriers showing limited biodistribution to tumor are either inorganic (gold, silica, iron oxide, quantum dots) or organic (dendrimers, liposomes polymers, hydrogels) rather than protein-based. Once administered in blood, non-protein-based nanocarriers are covered by a protein corona that changes the conformation of the nanocarrier surface and undergo intensive phagocytosis by resident macrophages in clearance organs. A completely different protein drug delivery system is represented by the targeted antibody-drug conjugates (ADC), which have lower loading capacity and flexibility for encapsulating various cargos and display a less controllable drug release kinetics compared to nanocarriers. Consequently, in clinical studies, only 0.001-0.01% of the injected antibody dose reaches the tumor, thus, although ADC are standard treatment in some neoplasias, protein nanocarriers could offer an enormous opportunity to improve drug delivery to tumors.

Our results on nanocarrier biodistribution in the SC tumor model demonstrate a specific co-localization of the nanocarrier together with the CXCR4 receptor in the cell membrane followed by their internalization, via endocytosis, to reach the cytosol of CXCR4+ DLBCL cells. Once inside the cytosol, the structure of the nanocarrier elicits endosomal escape and delivery of the materials into the cytoplasm, before its ultimate intracellular proteolysis.

Furthermore, the efficacy of a T22-GFP-H6 nanocarrier that targets CXCR4+ DLBCL cells appears to be exclusively dependent on the overexpression of CXCR4 receptor in the membrane of tumor cells. This notion is currently supported by two main findings: on the one hand, T22-GFP-H6 displays a tumor uptake significantly higher than that achieved in the same SC tumor when CXCR4 is inhibited by AMD3100 in the competition assay. On the other hand, T22-GFP-H6 administration to mice bearing CXCR4+ SC SUDHL-2 tumors shows significantly higher uptake than CXCR4- SC SUDHL-2 tumors. Moreover, we confirmed the capacity of T22-GFP-H6 to internalize in CXCR4+ mouse cells, similar to our findings in CXCR4+ human cells. Thus, the high T22-GFP-H6 tumor uptake, and its low uptake in non-tumor organs, is necessarily related to the huge CXCR4 overexpression in DLBCL lymphoma cells and the negligible or low CXCR4 expression in normal organs, including BM mouse hematopoietic cells.

Importantly, in the disseminated CXCR4+ DLBCL mouse model, involving BM and LN, this nanocarrier also shows a high tumor uptake in the organs affected by CXCR4+ lymphoma cells, while displaying low biodistribution to normal tissues (with low or null CXCR4 expression). Unlike low molecular weight drugs that passively diffuse to all cells in the body, the biodistribution of the nanocarrier, or drug-loaded nanocarriers, is limited by their size; thus, it becomes highly dependent on the physiology and anatomy of specific organs in the body. Nanocarriers are unable to access organs irrigated by vessels with continuous endothelia and unable to penetrate membranes, unless they are actively targeted for endocytosis. Our protein nanocarrier can accumulate in the sinusoids of BM and LN infiltrated with tumor cells because they display vascular beds with discontinuous endothelium and 100-200nm fenestrations that allow the transport of macromolecules, including nanocarriers. Moreover, as we have showed in the SC mouse model, T22-GFP-H6 also has the capacity to internalize specifically in the CXCR4+ DLBCL cells, here localized in BM and LN in the DLBCL disseminated model. Even though there is no consistent EPR effect in hematologic neoplasias, the structure of the vessels in the sinusoids of the DLBCL niches and the active targeting to CXCR4 allow T22-GFP-H6 accumulation and internalization in the tumor niches that are infiltrated by CXCR4+ DLBCL cells.

Given the high selectivity that T22-GFP-H6 achieves in targeting CXCR4+ DLBCL cells within the tumor, we used the SC CXCR4+ Toledo model to test the antitumor activity of T22-DITOX-H6, a therapeutic nanoparticle derived from this nanocarrier that incorporates the diphtheria cytotoxic domain. This therapeutic nanoparticle induced a high level of apoptotic cell death in tumor tissue without toxicity, since it did not induce any macroscopic or histo-
logical alteration in normal organs, including the BM. The higher levels of CXCR4 expression in DLBCL cells, as compared to normal hematopoietic cells in the BM, were likely responsible for the cytotoxic activity, observed exclusively in tumor cells. These data confirm the potential of the studied protein nanocarrier to be used as a platform for the delivery of antitumor agents to DLBCL cells. We have previously described also the potential use of T22-GFP-H6 as an antitumor drug delivery agent for the treatment of colorectal cancer and leukemia. To our knowledge, no protein-based therapeutic nanoparticle has been previously reported as a possible drug carrier for lymphoma therapy.

So far, most research studies for DLBCL therapy targeting CXCR4 are performed with CXCR4 antagonists (e.g. plerixafor or BKT140) or inverse agonists (e.g. IQL-01). Our approach differs from these studies since it is not focused on inhibiting signaling downstream of the CXCR4 receptor, but, in delivering high concentrations of potent therapeutic agents to specifically kill CXCR4+ lymphoma cells. The active delivery of the drug-loaded nanocarriers only to CXCR4+ cells should increase the therapeutic index compared to low molecular weight CXCR4 inhibitors, which biodistribute to all tissues independently of their CXCR4 expression. In conclusion, specifically eliminating CXCR4+ DLBCL cells could be an effective strategy to enhance the survival and cure rates observed in R-CHOP refractory or relapsed patients.

Acknowledgments

The authors would like to thank Annabel García-León (IIB-Catalunya CERCA Programme) and a Miguel Serveit contract from ISCIII to MVC. The bioluminescent follow-up of cancer cells and nanoparticle biodistribution and toxicity studies have been performed in the ICTS-141007 Nanbiosis Platform, using its CIBER-BBN Nanotoxicology Unit (www.nanbiosis.es/portfolio/u18-nanotoxicology-unit/). Protein production has been partially performed by the ICTS “NANBIOSIS”, more specifically by the Protein Production Platform of CIBER-BBN/ IBB (www.nanbiosis.es/unit/u1-protein-production-platform-ppp/).

References

1. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–5032.

2. Kupiec-Weglinski JS, Blum KA, Kahl BS, et al. Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. J Natl Cancer Inst. 2016;108(12).

3. Culleru JL, Dalia SM. Diffuse large B-cell lymphoma: current strategies and future directions. Cancer Control. 2012;19(3):204–213.

4. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23(18):4117–4127.

5. Philip T, Guglielmi C, Hagenbeck A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–1545.

6. Gisselbrecht C, Glass B, Moulinier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–4190.

7. Chen J, Xu-Monette ZY, Deng L, et al. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinat center B-cell-like diffuse large B-cell lymphoma. Oncotarget. 2015;6(8):5597–5614.

8. Moreno MJ, Bosch R, Dieguez-Gonzalez R, et al. CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival. J Pathol. 2015;235(5):442–450.

9. Xu Z-Z, Shen J-K, Zhao S-Q, Li J-M. Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2018;59(6):1451–1460.

10. Reinholdt L, Laursen MB, Schmitz A, et al. CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines. Biomark Res. 2016;4:12.

11. Domanska UM, Kruizinga RC, Nagenast WB, et al. A review on CXCR4/CXCL12 axis in oncology: No place to hide. Eur J Cancer. 2013;49(1):219–230.

12. Bertolini F, Dell’Agnola C, Mancuso P, et al. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin’s lymphoma. Cancer Res. 2002;62(11):3106–3112.

13. Kuhne MR, Mulvey T, Belanger B, et al. BMS-986548/MDX-1388: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2015;19(2):357–366.

14. Reinholdt LR, Laursen MB, Falgreen S, et al. High expression of CXCR4 impairs anti-CD20 monoclonal antibody (rituximab)-dependent cytotoxicity in diffuse large B-cell lymphoma. Blood. 2015;126(23):1455–1455.

15. Beider K, Ribakovsky E, Abraham M, et al. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140. Clin Cancer Res. 2015;19(15):3495–3507.

16. Unzueta U, Céspedes MV, Ferrer-Miralles N, et al. Intracellular CXCR4+ cell targeting with T22-empowered protein-only nanoparticles. Int J Nanomedicine. 2012;7:4533–4544.

17. Céspedes MV, Unzueta U, Tatkievich W, et al. In vivo architectonic stability of de novo designed protein-only nanoparticles. ACS Nano. 2014;8(5):4166–4176.

18. Sánchez-García L, Serna N, Álamo P, et al. Self-assembling toxin-based nanoparticles as self-delivered antitumoral drugs. J Control Release. 2018;274:81–92.

19. Serna N, Sánchez-García L, Unzueta U, et al. Protein-Based Therapeutic Killing for Cancer Therapeutics. Trends Biotechnol. 2018;36(3):318–335.

20. Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018;9(1):1410.

21. Firollo KE, Chang EH. Does a targeting ligand influence nanoparticle tumor localization or uptake? Trends Biotechnol. 2008;26(10):552–558.
22. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release. 2012;161(2):175–187.

23. Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release. 2011;153(3):196–205.

24. Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1(5):16014.

25. Céspedes MV, Unzueta U, Alamo P, et al. Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4+ colorectal cancer models. Nanomedicine. 2016;12(7):1987–1996.

26. Heneweer C, Holland JP, Divilov V, Carlin S, Lewis JS. Magnitude of enhanced permeability and retention effect in tumors with different phenotypes: 89Zr-albumin as a model system. J Nucl Med. 2011;52(4):625–633.

27. Unzueta U, Céspedes MV, Vázquez E, Ferrer-Miralles N, Mangues R, Villaverde A. Towards protein-based viral mimetics for cancer therapies. Trends Biotechnol. 2015;33(5):253–258.

28. Zhou S, Wu D, Yin X, et al. Intracellular pH-responsive and rituximab-conjugated mesoporous silica nanoparticles for targeted drug delivery to lymphoma B cells. J Exp Clin Cancer Res. 2017;36(1):24.

29. Nevala WK, Butterfield JT, Sutor SL, Knaur DJ, Markovic SN. Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20+ B-cell lymphoma. Sci Rep. 2017;7:45682.

30. Salvati A, Pitek A5, Monopoli MF, et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol. 2015;12(2):137–143.

31. Gustafson HH, Holt-Casper D, Grainger DW, Ghandehari H. Nanoparticle uptake: the phagocyte problem. Nano Today. 2015;10(4):487–510.

32. Zhang RX, Li J, Zhang T, et al. Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy – an illustration with firsthand examples. Acta Pharmacol Sin. 2018;39(5):825–844.

33. Gerber HP, Senter PF, Grewal IS. Antibody drug-conjugates targeting the tumor vasculature: Current and future developments. M Abs. 2009;13(8):247–253.

34. Garnett MC, Kallinteri P. Nanomedicines and nanotoxicology: some physiological principles. Occup Med. 2006;56(5):307–311.

35. Ghitescu L, Robert M. Diversity in unity: the biochemical composition of the endothelial cell surface varies between the vascular beds. Microsc Res Tech. 2002;57(9):381–389.

36. Ribatti D, Vaccar A, Nico B, Fanelli M, Roncali L, Dammarco E. Angiogenesis spectrum in the stroma of B-cell non-Hodgkin’s lymphomas. An immunohistochemical and ultrastructural study. Eur J Haematol. 1996;56(1–2):45–53.

37. Kobayashi H, Watanabe R, Choyke PL. Improving conventional Enhanced permeability and Retention (EPR) effects; what is the appropriate target? Theranostics. 2013;4(1):81–89.

38. Céspedes MV, Unzueta U, Aviñó A, et al. Selective depletion of metastatic stem cells as therapy for human colorectal cancer. EMBO Mol Med. 2018;10(10).

39. Díaz R, Pallarés V, Cano-Garrido O, et al. Selective CXCR4+ Cancer Cell Targeting and Potent Antineoplastic Effect by a Nanostructured Version of Recombinant Rucm. Small. 2018;14(26):e1806665.

40. Recasens-Zorzo C, Cardesa-Salzmann T, Petazzi P, et al. Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma. Haematologica. 2019;104(4):778–788.

41. Aghanejad A. Synthesis and Evaluation of [67Ga]-AMD3100: A Novel Imaging Agent for Targeting the Chemokine Receptor CXCR4. Sci Pharm. 2014;82(1):29–42.

42. Zhang X-X, Sun Z, Guo J, et al. Comparison of 18F-labeled CXCR4 antagonist peptides for PET imaging of CXCR4 expression. Mol Imaging Biol. 2015;15(6):758–767.